ERBB2 and breast cancer: The noticeable anti-tumor effect at molecular and cellular level of denosumab, when combined with anti-ERBB2 agents in ERBB2-positive BC cells, raises the possibility for therapeutic strategies with existing drugs, at least in a specific BC subgroup of RANK-expressing ERBB2-positive patients.